Delta-8 THC Metabolism: What CYP2C9 Experiments Can and Cannot Predict
Laboratory experiments identify CYP2C9 as an important enzyme for forming 11-hydroxy-delta-8-THC, particularly in intestinal preparations. They do not establish how long a person with a particular genotype will remain intoxicated, test positive, or clear delta-8 THC from the body.
The evidence comes from enzyme preparations
The researchers studied recombinant human enzymes expressed in cell-derived microsomes, together with pooled human liver and intestinal microsomes. These are in-vitro systems. Human-derived material does not make the experiment a clinical trial in people who consumed delta-8 products.
The measured endpoint was formation of 11-hydroxy-delta-8-THC in incubation mixtures, quantified by liquid chromatography–tandem mass spectrometry. It was not a patient’s blood concentration, urine detection window, driving performance or adverse-event rate.
Intestinal and liver findings were different
Among the screened recombinant enzymes, CYP2C9 showed the strongest activity; CYP2C19 had detectable but substantially lower activity. Other screened enzymes did not show detectable formation under the tested conditions. The kinetics of CYP2C9 resembled the intestinal preparation more closely than the liver preparation.
The liver result is an important qualification. The authors report that inhibitors directed at CYP2C9 and CYP2C19 produced little inhibition of metabolite formation in liver microsomes, suggesting contributions from enzymes not adequately captured by the screening panel. The paper therefore does not establish one enzyme as the complete explanation for hepatic delta-8 metabolism.
A genetic effect is a hypothesis about patients
Several CYP2C9 variants had reduced metabolite-formation efficiency compared with the reference enzyme. That supports clinical investigation of genetic variability. It does not directly measure genotype-specific exposure in people or prove a proportional change in intoxication.
Metabolite formation and removal of parent drug are related but different questions. A pathway that changes formation of an active metabolite cannot be translated into a simple multiplier for impairment without measuring both pharmacokinetics and effects.
Limits that matter in an expert opinion
The study used delta-9 THC binding estimates as a surrogate because delta-8’s unbound fraction was not independently characterized. Limited solubility also constrained high-concentration experiments. These assumptions affect interpretation of kinetic estimates.
An opinion about an actual specimen should identify the THC isomer, analytical method, product, route, timing and relevant clinical evidence. This paper supplies mechanistic evidence for variability, rather than a validated genetic clock or an individual impairment calculation.
Related analysis: Concentration Is Not Impairment: THC Blood Levels in California Driving Cases.
Primary research
Mengqi Zhao and colleagues. Cytochrome P450-Catalyzed Hydroxylation of Δ8-Tetrahydrocannabinol and Implications for Pharmacogenetics. Pharmaceutics (2026). DOI: 10.3390/pharmaceutics18091149.
